Personalized Medicine Study for Heart Attack Patients Begins in Germany

Share Article

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience

Spartan RX: On-demand DNA testing

For the first time, we can get genetic results at the time of cardiac stenting. -Tobias Geisler, M.D.

Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study is part of a larger clinical trial entitled “Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes Trial (TROPICAL-ACS)”. TROPICAL-ACS, led by principal investigator Dirk Sibbing, M.D., aims at investigating a safe way of de-escalating antiplatelet treatment in ACS patients undergoing cardiac stenting.

The Spartan RX CYP2C19 System is being used to test heart attack patients receiving cardiac stents. Half of the patients are receiving Effient® (prasugrel) for 12 months. The other half are being treated with prasugrel for one week, and then switched to Plavix® (clopidogrel) for one week. If patients respond to clopidogrel, they are kept on the drug. Otherwise, they are switched back to prasugrel.

The principal investigator of the Spartan study is Tobias Geisler, M.D., and his collaborators are Dirk Sibbing, M.D., and Dietmar Trenk, M.D. Patients are being enrolled at University Clinic of Tuebingen, Munich University Clinic, and Heart Center Bad Krozingen.

“We are delighted to use Spartan’s rapid CYP2C19 genotyping system as part of the TROPICAL-ACS study,” said Tobias Geisler, M.D. “For the first time, we can get genetic results at the time of cardiac stenting.”

“Genotyping patients with the Spartan RX CYP2C19 System is an important complement to phenotyping by means of platelet function testing with the Multiplate® Analyzer,” said Dirk Sibbing, M.D.

About CYP2C19
The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(1), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(2,3,4,5)

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(6) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at:

The Spartan logo is a registered trademark of Spartan Bioscience Inc.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.
Effient is a registered trademark of Eli Lilly and Company.
Multiplate is a registered trademark of Roche Diagnostics International Ltd.

1. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
3. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
4. Oh IY et al. (2012). Heart. 98(2):139–44.
5. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.
6. Roberts JD et al. (2012). Lancet. 379:1705–11.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kira Watson
Spartan Bioscience Inc.
+1 613-228-7756 Ext: 708
Email >
Visit website